Scientists warn of premature optimism as drugmakers rally
They point out that the drugs of some companies are still in early stages, and may never pass clinical trials or gain regulatory approval
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
THERE is big money to be made in producing a vaccine for Covid-19, and investors' interest in which pharmaceutical and biotech company will cross the finish line first is causing a global rally in these stocks.
But analysts and scientists warn that such hopes have also lifted the shares of smaller companies, the products of which are only in early stages of development, perhaps years away from getting to market. There is also no guarantee that these experimental drugs will pass clinical trials and obtain regulatory approval.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute